MIT Technology Review January 3, 2025
Jessica Hamzelou

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

In June 2024, results from a trial of a new medicine to prevent HIV were announced—and they were jaw-dropping. Lenacapavir, a treatment injected once every six months, protected over 5,000 girls and women in Uganda and South Africa from getting HIV. And it was 100% effective.

The drug, which is produced by Gilead, has other advantages. We’ve had effective pre-exposure prophylactic (PrEP) drugs for HIV since 2012, but these must be taken either daily or in advance of each time a person is exposed to the virus. That’s a big ask for healthy people. And because these medicines also...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
Q&A: Nutritional Pharmacist's Perspective on New Year Dieting Trends
Open Source in Life Sciences: Balancing Innovation and Compliance
The hidden traps of business building: A guide for life science CEOs
Walgreens CEO: ‘Turnaround Will Take Time’

Share This Article